Abstract
Background and Aims: Despite concerns about high prevalence of hepatitis C virus (HCV), psychiatry patients have been underserved due to neuropsychiatric adverse effects of interferon therapy. Directly acting antiviral (DAA) agents have made treatment of HCV in these patients feasible. In view of the paucity of information about prevalence of HCV in this group in Australia, and since an admission for mental illness may offer an opportunity for screening and treatment of HCV, this study was undertaken. Aims of this study were to assess inpatients admitted to hospital with mental illness: (1) HCV seroprevalence (2) prevalence of risk factors for HCV and (3) experience of treatment and follow-up.
Original language | English |
---|---|
Pages (from-to) | S165-S166 |
Number of pages | 2 |
Journal | Journal of Hepatology |
Volume | 68 |
Issue number | S1 |
DOIs | |
Publication status | Published - Apr 2018 |
Event | International Liver Congress 2018 - Paris expo Porte de Versailles, Paris, France Duration: 11 Apr 2018 → 15 Apr 2018 |
Keywords
- Hepatitis C
- Risk factors
- Psychiatric inpatients
- Interferon therapy